Cogent Biosciences, Inc.

NasdaqGS:COGT Voorraadrapport

Marktkapitalisatie: US$1.3b

Cogent Biosciences Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Andy Robbins

Algemeen directeur

US$7.9m

Totale compensatie

Percentage CEO-salaris8.3%
Dienstverband CEO4.1yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn3.8yrs
Gemiddelde ambtstermijn bestuur4.3yrs

Recente managementupdates

Recent updates

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Sep 04
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Cogent Biosciences: Inflection Year Directly Ahead

Jun 23

Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

May 22
Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans

Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst

Feb 14

Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Nov 27
Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Jun 20
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Mar 05
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Nov 18
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation

Cogent Biosciences: What's Ahead

Sep 13

Cogent Biosciences: APEX Data Was Interesting, But We Need More

Jun 26

Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Jun 10
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?

Cogent Biosciences names new chief legal officer

May 03

What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition

Mar 17
What You Need To Know About Cogent Biosciences, Inc.'s (NASDAQ:COGT) Investor Composition

Cogent Biosciences gets Piper Sandler nod on Kiq acquisition

Dec 23

Cogent Biosciences prices upsized $100M equity offering

Dec 02

Cogent Bio launches $60M equity offering, shares down 7%

Nov 30

Cogent Bio reports data from PLX9486 combo trial in GIST patients

Nov 18

Cogent Biosciences EPS misses by $4.91

Nov 09

Analyse CEO-vergoeding

Hoe is Andy Robbins's beloning veranderd ten opzichte van Cogent Biosciences's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$227m

Mar 31 2024n/an/a

-US$212m

Dec 31 2023US$8mUS$656k

-US$192m

Sep 30 2023n/an/a

-US$178m

Jun 30 2023n/an/a

-US$157m

Mar 31 2023n/an/a

-US$148m

Dec 31 2022US$4mUS$624k

-US$140m

Sep 30 2022n/an/a

-US$126m

Jun 30 2022n/an/a

-US$110m

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$3mUS$593k

-US$72m

Sep 30 2021n/an/a

-US$163m

Jun 30 2021n/an/a

-US$194m

Mar 31 2021n/an/a

-US$185m

Dec 31 2020US$18mUS$102k

-US$179m

Compensatie versus markt: De totale vergoeding ($USD 7.90M ) Andy } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.57M ).

Compensatie versus inkomsten: De vergoeding van Andy is gestegen terwijl het bedrijf verliesgevend is.

CEO

Andy Robbins (48 yo)

4.1yrs

Tenure

US$7,898,772

Compensatie

Mr. Andrew R. Robbins, also known as Andy, M.B.A., serves as Chief Executive Officer, President and Director at of Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.) since October 23, 2020. He was...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Andrew Robbins
President4.1yrsUS$7.90mgeen gegevens
John Robinson
Chief Scientific Officer3.6yrsUS$2.98m0%
$ 0
Jessica Sachs
Chief Medical Officer5.4yrsUS$3.00m0.0012%
$ 14.8k
John Green
CFO & Principal Accounting Officer4.3yrsUS$2.14mgeen gegevens
Brad Barnett
Chief Technology Officer4yrsgeen gegevensgeen gegevens
Christi Waarich
Senior Director of Investor Relationsno datageen gegevensgeen gegevens
Evan Kearns
Chief Legal Officer & Corporate Secretary3.5yrsgeen gegevensgeen gegevens
Erin Schellhammer
Chief People Officerno datageen gegevensgeen gegevens
Dana Martin
Senior VP of Medical Affairs & Chief Patient Officerno datageen gegevensgeen gegevens
Brad Fell
Senior Vice President of Chemistryno datageen gegevensgeen gegevens
Rachael Easton
VP & Head of Clinical Development2yrsgeen gegevensgeen gegevens
Ben Exter
Senior VP and Head of Regulatory & Pharmacovigilanceless than a yeargeen gegevensgeen gegevens

3.8yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van COGT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Andrew Robbins
President4.1yrsUS$7.90mgeen gegevens
Arlene Morris
Independent Director5.3yrsUS$345.49k0%
$ 0
Matthew Ros
Independent Director5.3yrsUS$336.69k0%
$ 0
Todd Shegog
Independent Director3.8yrsUS$345.80k0%
$ 0
Kwok-Kin Wong
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Karen Jean Ferrante
Independent Director6.8yrsUS$340.37k0%
$ 0
Michael Vasconcelles
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Ryan Corcoran
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Christopher Cain
Independent Director4.3yrsUS$341.36k0%
$ 0
Peter Harwin
Independent Chairman of the Board4.3yrsUS$364.55k0%
$ 0
Srdan Verstovsek
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Sylvia Adams
Member of Scientific Advisory Board1.8yrsgeen gegevensgeen gegevens

4.3yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van COGT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).